ABSTRACT Background: Home parenteral nutrition (HPN) and intestinal transplantation (ITx) are the 2 treatment options for irreversible intestinal failure (IF). Objective: This study simulated the disease course of irreversible IF and both of these treatments-HPN and ITx-to estimate the cost-effectiveness of ITx. Design: We simulated IF treatment in adults as a discrete event model with variables derived from the Dutch Registry of Intestinal Failure and Intestinal Transplantation, the Intestinal Transplant Registry, hospital records, the literature, and expert opinions. Simulated patients were enrolled at a rate of 40/mo for 10 y. The maximum follow-up was 40 y. Survival was simulated as a probabilistic function. ITx was offered to 10% of patients with ,12 mo of remaining life expectancy with HPN if they did not undergo ITx. Costs were calculated according to Dutch guidelines, with discounting. We evaluated the cost-effectiveness of ITx by comparing models conducted with and without ITx and by calculating the cost difference per lifeyear gained [incremental cost-effectiveness ratio (ICER)]. Results: The average survival was 14.6 y without ITx and 14.9 y with ITx. HPN costs were V13,276 for treatment introduction, followed by V77,652 annually. The costs of ITx were ∼V73,000 during the first year and then V13,000 annually. The ICER was V19,529 per life-year gained. Conclusion: Our simulations show that ITx slightly improves survival of patients with IF in comparison with HPN at an additional cost of V19,529 per life-year gained.
INTRODUCTION
Intestinal failure (IF) 5 is defined as the reduction in functioning gut mass below the minimal amount necessary to maintain an acceptable nutritional status with an enteral diet. This condition can result from surgery, functional bowel disease, or a congenital defect.
Short bowel syndrome is the most common cause of IF and occurs when 70-75% of small bowel length has been lost due to previous surgery (1) (2) (3) (4) . IF becomes irreversible when the gastrointestinal tract is unable to compensate for loss of length, function, or both. Until the advent of total parenteral (intravenous) nutrition (TPN) in the 1960s, irreversible IF was considered incompatible with life. TPN administered at homehome parenteral nutrition (HPN)-is the main treatment of irreversible IF.
Irreversible IF is rare, with a reported prevalence in Europe ranging from 1.1 to 12.7 per million adults. The Dutch prevalence was reported to be 3.7 per million adults in 1997 (5) . Recent results from the Dutch Registration of Intestinal Failure and Intestinal Transplantation (DRIFT) point to a prevalence of 10.3 per million on January 2013, which indicates a considerable increase over the past 16 y.
HPN allows patients with IF to live outside the hospital and meet their nutritional requirements, although serious complications often occur, such as parenteral nutrition-associated liver disease, vascular access problems, sepsis, and metabolic derangement. Patient survival mainly depends on the underlying disease. IF, including HPN-related complications and associated social restrictions, often leads to substantial psychosocial distress and impaired quality of life (QoL) (6, 7) .
From a socioeconomic perspective, the health care burden of irreversible IF is enormous. The estimated annual costs for maintenance nutritional support differ widely: reported amounts vary between $75,000 and $300,000 per patient (8, 9) .
Intestinal transplantation (ITx) is a relatively new therapeutic alternative to HPN (10) . For patients with IF, the prognosis with HPN-a 5-y survival rate of 75-85% (11, 12) -is superior to the prognosis after ITx, which yields a 3-to 5-y survival of 69% and 56%, respectively (13) . Most recently, however, worldwide 5-y survival rates from the Intestinal Transplant Registry (ITR) approached 70%. ITx should be reserved for patients with IF with life-threatening complications from HPN, the so-called failure of HPN (14) . For these "high risk" patients, survival clearly improves after ITx in comparison to continued HPN, and these patients have high mortality rates while on the waiting list for ITx (14) .
Although a few studies discuss the costs of HPN and ITx (9, 15) , no study has definitively established the cost-effectiveness of ITx (8) . Extensive and exact data on costs are lacking, but according to the literature, ITx may become cost-effective after ∼1-2 y in patients who retain their functional grafts (9) .
In The Netherlands, the University Medical Center Groningen is the national center for ITx, where this procedure has been performed since 2001 in adults and children. HPN is provided by 2 specialized centers for children and adults (Amsterdam Medical Center and University Medical Center Nijmegen, St. Radboud) throughout the country. The aim of this study was to evaluate the disease course of irreversible IF and the treatment effects of HPN and ITx and to estimate cost-effectiveness of ITx on the basis of national and international data by using a simulation model.
METHODS

Model structure
We simulated the treatment options for irreversible IF in adults in a cohort-based discrete event model. Discrete event modeling requires the clinical course of patients to be represented as a series of consecutive steps or states. The time spent in the various states is programmed in the model as fixed durations or as timedependent probabilities, depending on what is the best approximation of the actual process being modeled. In addition, treatment choices can be modeled by fixed probabilities or by comparing multiple time-dependent probabilities.
We modeled the treatments HPN and ITx, with subsequent graft failure or sustained graft function, and death as the final state ( Figure 1) . The amount of time that the simulated patients remained in each treatment state (transition time) was determined by probabilistic Weibull functions. These functions resemble survival curves, and their shape was based on the available data. For each patient, the duration of a certain state was randomly drawn from the distribution of the respective Weibull function. In case of multiple possible outcomes, transition times were determined independently for each outcome and the shortest time determined the outcome.
Selection for ITx was determined by a fixed percentage of patients with a remaining life expectancy with HPN of ,12 mo. Maximum simulated follow-up was 40 y, in view of the average age of adult patients with irreversible IF (median age of adults in the DRIFT registry of 54 y). During execution of the model, detailed information was collected about time spent in the various states in the model. To produce stable estimates, the model was replicated 500 times. In each replication of the model, all outcomes were calculated for the entire cohort of included patients. The model was constructed with the use of advanced and generic modeling software (AnyLogic Company).
Model variables
We derived variables for our model from the International ITR (patient and graft survival), the DRIFT (patient inflow, HPN survival), hospital records, expert opinions from Dutch HPN centers and the ITx center ( Table 1) , and from the literature (3, 8, 9, 16, 17, 22) . Although the number of new IF patients in The Netherlands was estimated at 4/mo, the simulations were performed with an enrollment rate of 40/mo, which means that we simulated a larger recruitment area of perhaps several European countries. This increase in number of patients does not affect absolute results, because the results are represented as the difference between the situations of HPN treatment without ITx and HPN with ITx. The larger number of patients does, however, improve accuracy. Over a simulation period of 10 y, 4800 patients were enrolled. After an initial period of HPN, ITx was offered to 10% of patients with a remaining life expectancy with HPN of ,12 mo. We also evaluated outcomes when higher percentages of patients (15% and 20%) were offered ITx and in the case of longer remaining survival expectancy (18, 24 , and 36 mo).
Survival with HPN was based on data from the literature (11, 12, 18) , whereas the Weibull curves for graft and patient survival after ITx were based on ITR data and extrapolated to 40 y ( Figure  2 ). Survival after graft failure was estimated on the basis of the difference between graft survival and patient survival after ITx. In view of the very short waiting list for an adult donor organ (19) , the probability of dying while waiting was considered negligible.
Costs
We calculated costs according to Dutch national guidelines at the price level of 2012 (20) and indexed pricing by using the Dutch consumer price index (www.cbs.nl). The costs of transplantation were based on a recent publication by van der Hilst et al. (17) , which reported the costs of adult liver transplantation until 1 y after surgery. The procedure and the costs associated with liver transplantation are comparable to ITx. However, according to the expert opinion from surgeons of the Dutch ITx center, ITx requires longer surgery and more use of blood products than does liver transplantation. We modeled these extra costs. Then, we calculated the costs of follow-up after the first year assuming 2 outpatient visits/y (including physician costs) and 6 d of hospital admissions/y (9, 21) , in addition to evaluations of intestinal function including endoscopies, as well as evaluations of kidney function and bone densitometry, all according to the local University Medical Center Groningen protocol. Costs of immunosuppressive medication were considered to remain the same after the first year. Costs of HPN onset were calculated separately from the annual costs of continuous HPN for 7 d/wk. Costs for onset included a hospital admission for HPN training, nursing staff time for training, physician costs, and initial HPN consumables, as well as central venous catheter placement and initial home care support. We derived these costs from a comprehensive evaluation of TPN by Olieman et al (22) with adaptations for the adult situation, mainly the quantity of HPN products used.
Cost-effectiveness
To estimate life-years with HPN and after ITx, we added up the numbers of patients in the HPN and ITx states per year. We calculated costs per month and per year by using the data on numbers of patients starting on HPN, numbers of patients receiving ITx, and numbers of patients in follow-up after the start of HPN or ITx. To account for the depreciation of future costs and effects, we applied discounts to the annual data for lifeyears and costs on the basis of the economic principle that benefits are worth more today than in the future because of the preference to spend now rather than later and because there may be improvements on interventions in the near future. This principle can be applied to costs as well as to health outcomes (23) . We discounted future costs and effects by 4.0% and 1.5%, respectively. For comparison with other countries, we applied uniform (uniform for costs and effects) discount rates of 3%, 4%, and 5%.
We evaluated the cost-effectiveness of ITx by comparing life-years and costs of 500 replications of the model with and without ITx as a treatment option. We combined model outputs with regard to life-years and numbers of patients with costs to calculate the incremental cost-effectiveness ratio (ICER)-defined as the difference in costs divided by the difference in life-years comparing the alternative intervention (ITx) to the standard (HPN). The ICER expresses the costs for the gain of a life-year.
RESULTS
Survival
All of the patients entered our simulation model over a period of 10 y. The number of patients receiving HPN was only slightly smaller than in simulations without ITx (Figure 3) . HPN patient numbers decreased steadily due to ITx or death. The number of patients alive after ITx peaked after ∼13 y at 71 patients (16.7% of the average number of 425 patients undergoing ITx) and then also declined (Figure 3, right y axis) . The cumulative number of ITx patients increased over the entire simulation period. At the end of the simulation period of 40 y, there were still patients left in both treatment groups: 595 patients remained on HPN (12.4% of the 4800 enrolled) and 18 patients remained in the ITx state (4.2%). The average number of deceased patients at the end of the simulations was 4187 (87% of the total enrolled). The number of transplants ranged from 362 to 480 between the model replications. In this model, the average survival was 14.6 y without ITx and 14.9 y with ITx.
Costs
The initial costs of HPN were V13,276, including clinical training and the placement of a central venous catheter. The average annual costs for HPN maintenance were V77,652 (Table  1) . These annual costs include HPN products, HPN nurse support, outpatient follow-up, home care, and hospital admission in case of HPN-related complications. The cost of ITx was V72,332 during the first year, including screening, the transplant procedure, and clinical and outpatient follow-up. The subsequent average annual cost was V15,183, which mainly arose from immunosuppression, rehospitalization, and outpatient followup (Table 1) .
Cost-effectiveness
Both total costs (V44.57 million) and life-years (1525 y) increased with ITx (10%) compared with HPN (Table 2, undiscounted). Total costs of HPN decreased by just over 11 million euros (0.2% of total costs) when ITx was introduced. However, in this situation, total costs of ITx amounted to V55 million. The combination of these outcomes resulted in an estimated V29,223 for each additional life-year gained by ITx. When we applied discounts, this estimate decreased to V19,529 per life-year.
HPN cost calculations were based on an assumed full need for HPN 7 d/wk. However, because some patients with irreversible IF only need HPN a few days a week, we may have overestimated HPN costs. Calculations with HPN of 4 d/wk instead of 7 resulted in an increase in the discounted costs per life-year by V2189.
When we selected higher percentages of patients for ITx, the numbers of transplantations, mean survival, life-years, and total costs proportionally increased, whereas costs of TPN proportionally decreased ( Table 2 ). The net result was that undiscounted costs per life-year remained virtually unchanged. After discounting, the cost-effectiveness with increased ITx percentages slightly improved, probably attributable to the fact that the lifeyears were less affected by the discounting procedure than were the costs.
Because the expected survival with HPN for ITx candidates might in fact be longer than 12 mo, analyses using expected survival times of 18, 24, and 36 mo were also conducted ( Table  3) . Without discounting, the increment of prognosis with HPN resulted in lower costs per life-year, and with higher ITx percentages. The decrement in costs in this situation outweighed the decrement in survival. With discounting, the increment of prognosis with HPN slightly increased the ICER. The decrement of survival relatively outweighs the decrement in costs in this situation. When we applied uniform discount rates for costs and effects of 3%, 4%, and 5%, this resulted in slightly less favorable ICERs. Applying a higher discount rate to effects clearly diminished the value of long-term gain in life-years with ITx.
Variations in costs of ITx and HPN had modest effects on the overall cost-effectiveness ( Table 4) . Increasing costs of ITx by 50% increased the costs per life-year by ∼60%, whereas a similar increase in costs of HPN decreased the cost-effectiveness of ITx by ∼10%. Simultaneous increases in costs of ITx and HPN by 50% and 20%, respectively, yielded outcomes for costs per lifeyear reflecting the counteracting effect of these changes.
DISCUSSION
The introduction of new modalities and treatment regimen in health care requires not only a demonstration of clinical superiority but also insight into costs for society. Especially in times of austerity, balancing medical innovation and patient needs with prioritization of reimbursement has become standard practice for national health care budgets. The best example in transplantation, which shows superiority of treatment, enhanced QoL, and significant reduction in cost is the comparison between hemodialysis and kidney transplantation, favoring the latter. The medical situation concerning patients who receive either permanent HPN or ITx is comparable but more complex because of the fact that clinical superiority and the effect on QoL are actually less clear. To our knowledge, no comprehensive comparison of the 2 existing treatment modalities for irreversible IF in adults has been published.
This simulation study enhances insight into the impact of ITx and its cost-effectiveness compared with HPN. According to our simulations, ITx improves patient survival by 3 mo over a 40-y follow-up when restricted to patients with a life expectancy of 12 mo who do not undergo transplantation, which is the actual situation to date. The absolute survival gain of 3 mo in this model may seem marginal. However, we have to consider that in this model the survival benefit of the 10% of transplanted patients is distributed over a large simulated population of whom 90% did not undergo ITx. Therefore, the appreciated survival benefit of an individual patient undergoing ITx will, in fact, be longer than 3 mo.
In our model, the cost per life-year gained was ∼V30,000. This amount is similar to liver transplantation and lower than for heart and lung transplantation (24, 25) . Studies reporting on the costs of HPN/TPN and ITx are scarce, although these therapies account for a great impact on the economic health care burden in The Netherlands, as well as in other developed countries worldwide. Our study confirms the high costs estimated for HPN therapy. Costs for HPN are composed of the continual need for high-priced nutritional infusion products and (to a lesser extent) by the costs for the onset of this therapy and for hospitalization in case of complications of HPN therapy. Total costs for ITx are composed mainly of hospitalization during the first year after the procedure, of the costs the procedure itself, and reinterventions, as well as lifelong continuous costs of expensive immunosuppressive medication.
For this study, we assumed that 10% of patients met the indications for ITx and would not survive beyond 1 y without ITx. Therefore, in our model, this percentage of patients progressed from the HPN state into the ITx state. This relatively small percentage reflects a strict handling of indications for ITx, which is the case in The Netherlands. But because indication rates have been increasing during the past decade, especially in high-volume centers, we also evaluated outcomes with higher percentages (14, 16, 19, 26) . When 15% and 20% of patients were selected for ITx, it improved survival and incurred higher costs with no substantial change in cost-effectiveness. This finding economically supports the further widening of the indication for ITx.
It is difficult to estimate the prognosis of an ITx candidate receiving HPN: allowing patients with a better prognosis results in higher percentages of selected ITx candidates. This prognosis could be longer than 12 mo. The sensitivity analysis of the estimated prognosis of the ITx candidate shows a decrease in ICER with extension of the prognosis without discounting and a marginal increase in the ICER with discounting. Therefore, the percentage of candidates selected for ITx (and their prognosis with HPN) seems not to have a major impact on the cost-effectiveness of ITx.
Although average costs of HPN exceed those of ITx within 2 y after the start of treatment, we cannot simply compare the 2 treatment options for the individual patient. There are 3 main reasons for this. First, ITx is now only offered to patients who would otherwise die within 12 mo, which would obviously be far most beneficial financially. Second, for each patient, the costs made for HPN before the ITx procedure is performed have to be taken into account. In this model, a percentage of patients went into the ITx status right from the start of a 40-y follow-up period. However, most patients will be in the more expensive TPN state before ITx is offered. Third, we cannot limit our comparison to the pure economic aspect of IF; the value of QoL with a certain treatment has to be taken into account. However, it is very In this study, we made calculations on the basis of direct costs only. From our own studies reporting on QoL, we know that 43% of HPN patients are unable to work and only 14% are economically active in society (6) . Most survivors after ITx reintegrate into society, with a self-sustained socioeconomic status (16) . However, frameworks for incorporating indirect costs of work absence or resumption are limited in this situation of IF with long-term absence. The friction cost method only allows costs up to a maximum period of ∼6 mo. The human capital method assumes lifelong friction costs and is therefore generally considered to overestimate costs of productivity loss (23) . We did include the costs for home care in the calculation of costs on HPN on the basis of the expert opinion that 50% of patients receive home care, which contributed considerably to total costs (27) . Finally, our results remain an assumption because they are based on a model that can only approximate reality.
At the most recent International Small Bowel Transplant Symposium in Oxford, United Kingdom, June 2013, it became clear that QoL, patient valuation, and an active patient role in the discussion about ITx are being considered and studied. We were not able to adjust life-years for quality of life in our model because no data exist. As an approximation, we used data from a recent evaluation of cost-effectiveness of preservation methods in kidney transplantation (28) . Assuming a utility of 0.66 on HPN and 0.9 after ITx, the overall utility of a life-year would be ,0.9, so with costs remaining unchanged, the costs per quality-adjusted life-year (QALY) gained would be higher than the costs per lifeyear (V31,787 undiscounted). However, due to the favorable gain of QoL after ITx, QALYs after ITx would constitute a higher proportion of total QALYs (3.1%) than without adjustment for QoL (2.3%). In the near future, we can imagine the broadening of indications if the expected improved QoL after ITx compared with HPN (16, 29) can be confirmed and if patient valuation and opinion are allowed to play a role in indicating ITx. Taking this into account and a possible further improvement of outcome after ITx, one could envisage offering ITx as a rehabilitative long-term treatment option to all patients with irreversible IF. In conclusion, our simulation model shows that ITx slightly improves life-years in patients with irreversible IF at relatively low cost.
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